Other Public Disclosures Sample Clauses
The "Other Public Disclosures" clause governs how parties may share information about their agreement or relationship with the public outside of formal announcements. Typically, it restricts or sets conditions on making statements, press releases, or other communications that reference the agreement, the parties involved, or related business dealings. For example, a party may need to obtain written consent before mentioning the partnership in marketing materials or responding to media inquiries. This clause serves to protect sensitive information, maintain control over public messaging, and prevent unauthorized or potentially damaging disclosures.
Other Public Disclosures. The Company and the Purchasers shall consult with each other in issuing any other public disclosure with respect to the transactions contemplated hereby, and none of the Company or any Purchaser shall issue any such public disclosure nor otherwise make any such public statement without the prior consent of the Company, with respect to any press release of any Purchaser, or without the prior consent of the Required Purchasers, with respect to any press release of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is reasonably viewed as required by any Regulation, in which case the disclosing party shall promptly provide the other party with prior notice of such public statement or communication. Notwithstanding the foregoing, the Company shall not publicly disclose the name, trademark, service m▇▇▇, symbol, logo (or any abbreviation, contraction or simulation thereof) of, or otherwise refer to, any Purchaser (including in any filing with the Commission, regulatory agency or Trading Market, including the Form 8-K filing referenced above) without the prior consent of the Purchaser (including in any press release, letterhead, public announcement or marketing material), except, and then only after consulting with such Purchaser, to the extent required to do so under applicable Regulations (including as required in any registration statement filed with the Commission). None of the Company Parties and their Affiliates shall represent that any Company Party or any of its Affiliates, any product or service of the Company Parties or their Affiliates, or any know how or policy or practice of the Company Parties or their Affiliates has been approved or endorsed by any Purchaser Party.
Other Public Disclosures. As between the Parties, subject to Section 3.6 and this Section 16.2, the Selling Party with respect to a country in the Territory shall have the primary responsibility for public communications regarding the Exploitation of the Territory Combination Product in such country(ies) hereunder. If either Party or its Affiliates desires to make a public announcement (such as a press release) that relates to the Exploitation of the Territory Combination Product in the Territory, other than with respect to Results, which are governed by Section 3.6, the announcing Party (or Affiliate) shall give reasonable advance notice [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT REQUESTED UNDER 17 C.F.R. §§ 200.80 (b)(4) AND 230.406 of the proposed text of such announcement (translated into English, if not in English) to the other Party for its prior review. Other than with respect to Results, which are governed by Section 3.6, (a) in the case of Tibotec as the announcing Party, any proposed public announcement that refers to the safety, efficacy or other characteristics of the Territory Combination Product or Gilead’s Single Agent Product(s) or Double Agent Product, shall be subject to prior approval by Gilead, such approval not to be unreasonably withheld and (b) in the case of Gilead as the announcing Party, any proposed public announcement that refers to the safety, efficacy or other characteristics of the Territory Combination Product or Tibotec’s Single Agent Product, shall be subject to prior approval by Tibotec, such approval not to be unreasonably withheld. Further, if any proposed public announcement by either Party that relates to the Exploitation of the Territory Combination Product uses any name or any Trademark of the other Party or its Affiliates (other than a Gilead Licensed Trademark or a Tibotec Licensed Trademark used in connection with Territory Combination Product), such public announcement shall be subject to prior approval of such other Party, except to the extent such announcement is required by Applicable Law. If the non-announcing Party with respect to any public announcement provided by the announcing Party for review under this Section 16.2 desires to provide comments or, if applicable, indicate whether the applicable public annou...